Bloomberg News

Intercell to Continue Study of Clostridium Vaccine Candidate

October 24, 2011

Oct. 24 (Bloomberg) -- Intercell AG, an Austrian vaccine maker, will continue the phase I clinical trial of a vaccine candidate against clostridium difficile, the major cause of nosocomial diarrhea, it said in a statement.

“Data show good safety and immunogenicity of the vaccine candidate and indicate functionality of the induced antibodies,” the Vienna-based company said in the statement.

Link to Statement:{NSN LTK3QI3PWT1C <GO>}

To contact the editor responsible for this story: Boris Groendahl at bgroendahl@bloomberg.net


Toyota's Hydrogen Man
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus